Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021;6(12):1072-1074.
doi: 10.1038/s41578-021-00385-x. Epub 2021 Oct 7.

Clinical translation of silica nanoparticles

Taskeen Iqbal Janjua #  1 , Yuxue Cao #  1 , Chengzhong Yu  2 , Amirali Popat  1   3
Affiliations

Clinical translation of silica nanoparticles

Taskeen Iqbal Janjua et al. Nat Rev Mater. 2021.

Abstract

Silica nanoparticles have entered clinical trials for a variety of biomedical applications, including oral drug delivery, diagnostics, plasmonic resonance and photothermal ablation therapy. Preliminary results indicate the safety, efficacy and viability of silica nanoparticles under these clinical scenarios.

Keywords: Drug delivery; Nanoparticles.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Clinical trials of silica nanoparticles.
The timeline shows different types of silica nanoparticle in clinical trials. cRGDY, cyclic arginyl-glycyl-aspartic acid-tyrosine; PEG, polyethylene glycol.
See this image and copyright information in PMC

References

    1. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update post COVID-19 vaccines. Bioeng. Transl Med. 2021;6:e10246. - PMC - PubMed
    1. Yang Y, Zhang M, Song H, Yu C. Silica-based nanoparticles for biomedical applications: from nanocarriers to biomodulators. Acc. Chem. Res. 2020;53:1545–1556. doi: 10.1021/acs.accounts.0c00280. - DOI - PubMed
    1. Tan A, Eskandar NG, Rao S, Prestidge CA. First in man bioavailability and tolerability studies of a silica–lipid hybrid (lipoceramic) formulation: a phase I study with ibuprofen. Drug Deliv. Transl Res. 2014;4:212–221. doi: 10.1007/s13346-013-0172-9. - DOI - PubMed
    1. Bukara K, et al. Ordered mesoporous silica to enhance the bioavailability of poorly water-soluble drugs: proof of concept in man. Eur. J. Pharm. Biopharm. 2016;108:220–225. doi: 10.1016/j.ejpb.2016.08.020. - DOI - PubMed
    1. Meola TR, Abuhelwa AY, Joyce P, Clifton P, Prestidge CA. A safety, tolerability, and pharmacokinetic study of a novel simvastatin silica-lipid hybrid formulation in healthy male participants. Drug Deliv. Transl Res. 2021;11:1261–1272. doi: 10.1007/s13346-020-00853-x. - DOI - PubMed